Zoetis (ZTS)

• Market cap: $71.9B
• 1 day: 1.93%
• 5 days: -2.15%
• 1 month: -4.22%
• 3 months: -9.20%
• 6 months: -12.27%
• Year to date: -1.32%
• 1 year: -14.82%
• 5 years: 12.82%
• 10 years: 252.04%
• Sector: Healthcare
• Industry: Pharmaceutical Preparations

About: Zoetis sells anti-infectives, vaccines, parasiticides, diagnostics, and other health products for animals. The firm earns roughly 35% of total revenue from production animals (cattle, pigs, poultry, and so on), and nearly 65% from companion animal (dogs, horses, cats) products. Its US business is skewed even more heavily toward companion animals, while its international business is slightly skewed toward production animals. The firm has the largest market share in the industry and was previously Pfizer's animal health unit.

Employees: 13,800

Fund manager confidence

Based on 2024 Q4 regulatory filings by fund managers ($100M+ AUM)

61% more first-time investments, than exits

New positions opened: 221 | Existing positions closed: 137

1% more funds holding

Funds holding: 1,749 [Q3] → 1,764 (+15) [Q4]

0.87% less ownership

Funds ownership: 92.92% [Q3] → 92.05% (-0.87%) [Q4]

10% less repeat investments, than reductions

Existing positions increased: 630 | Existing positions reduced: 700

17% less capital invested

Capital invested by funds: $81B [Q3] → $67.6B (-$13.4B) [Q4]

20% less call options, than puts

Call options by funds: $205M | Put options by funds: $258M

48% less funds holding in top 10

Funds holding in top 10: 25 [Q3] → 13 (-12) [Q4]

Research analyst outlook

6 Wall Street Analysts provided 1 year price targets over the past 3 months

• Low target: $180 12% upside
• Avg. target: $212 32% upside
• High target: $244 52% upside

6 analyst ratings

• positive: 5 83%
• neutral: 1 17%
• negative: 0 0%

Barclays Balaji Prasad 38% 1-year accuracy 16 / 42 met price target	52% upside $244	Overweight Maintained	14 Feb 2025
Morgan Stanley Erin Wright 50% 1-year accuracy 14 / 28 met price target	48% upside $238	Overweight Maintained	14 Feb 2025
Piper Sandler David Westenberg 51% 1-year accuracy 21 / 41 met price target	25% upside $200	Overweight Maintained	10 Feb 2025
Stifel Jonathan Block 10% 1-year accuracy 2 / 20 met price target	12% upside $180	Buy Maintained	7 Jan 2025
UBS	22% upside $196	Neutral Initiated	9 Dec 2024